Rathbones Group PLC Lowers Position in Pfizer Inc. $PFE

Rathbones Group PLC lessened its position in Pfizer Inc. (NYSE:PFE) by 5.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 447,525 shares of the biopharmaceutical company’s stock after selling 27,010 shares during the quarter. Rathbones Group PLC’s holdings in Pfizer were worth $11,143,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at approximately $29,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.5%

Shares of NYSE:PFE opened at $25.93 on Friday. The stock has a fifty day simple moving average of $26.88 and a two-hundred day simple moving average of $26.23. The stock has a market capitalization of $147.76 billion, a price-to-earnings ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a 12-month low of $22.81 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is presently 131.30%.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Wolfe Research restated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Morgan Stanley lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.61.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced strong Phase 2 results for its investigational 25-valent pneumococcal vaccine in infants, including a stronger immune response than Prevnar 20 and up to 15-fold higher antibody levels against a key strain. The company is now moving the program into pivotal Phase 3 testing, which could support future vaccine growth. Article Title
• Positive Sentiment: The company also received a broader European indication for HYMPAVZI, adding another recent R&D win that may strengthen Pfizer’s hemophilia franchise and improve investor confidence in the pipeline. Article Title
• Positive Sentiment: Pfizer and Rigel Pharmaceuticals expanded a commercialization deal for VEPPANU (vepdegestrant), creating another potential partnership-driven revenue stream tied to oncology. Article Title
• Positive Sentiment: Pfizer’s oncology growth story is also getting attention, with coverage pointing to Padcev, biosimilars, and late-stage pipeline assets as key long-term drivers. Article Title
• Neutral Sentiment: Pfizer was also listed as a participant in an AI industry summit, but this appears unrelated to the company’s core investment thesis and is unlikely to move the stock on its own. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.